The University of Chicago Header Logo

Connection

Michael H. Davidson to Fatty Acids, Omega-3

This is a "connection" page, showing publications Michael H. Davidson has written about Fatty Acids, Omega-3.
Connection Strength

7.489
  1. The clinical black, white, and gray lessons. Curr Opin Lipidol. 2021 04 01; 32(2):151-156.
    View in: PubMed
    Score: 0.763
  2. Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. Cardiol Clin. 2018 May; 36(2):277-285.
    View in: PubMed
    Score: 0.615
  3. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag. 2016; 12:481-490.
    View in: PubMed
    Score: 0.567
  4. The future of n-3 polyunsaturated fatty acid therapy. Curr Opin Lipidol. 2016 12; 27(6):570-578.
    View in: PubMed
    Score: 0.565
  5. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2014 Apr; 106(4):dju019.
    View in: PubMed
    Score: 0.470
  6. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013 Dec; 24(6):467-74.
    View in: PubMed
    Score: 0.459
  7. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014 Jan-Feb; 8(1):94-106.
    View in: PubMed
    Score: 0.455
  8. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013; 9:563-73.
    View in: PubMed
    Score: 0.454
  9. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.
    View in: PubMed
    Score: 0.451
  10. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012 Nov-Dec; 6(6):573-84.
    View in: PubMed
    Score: 0.404
  11. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol. 2011 Dec; 22(6):437-44.
    View in: PubMed
    Score: 0.400
  12. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):391-409.
    View in: PubMed
    Score: 0.308
  13. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006 Aug 21; 98(4A):27i-33i.
    View in: PubMed
    Score: 0.273
  14. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. Lipids Health Dis. 2020 May 30; 19(1):117.
    View in: PubMed
    Score: 0.180
  15. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
    View in: PubMed
    Score: 0.160
  16. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. J Clin Lipidol. 2018 Mar - Apr; 12(2):321-330.
    View in: PubMed
    Score: 0.150
  17. Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2017 Oct; 42(5):815-825.
    View in: PubMed
    Score: 0.150
  18. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol. 2016 Nov - Dec; 10(6):1442-1451.e4.
    View in: PubMed
    Score: 0.139
  19. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2014 Sep; 12(9):1045-54.
    View in: PubMed
    Score: 0.120
  20. Marine oil capsule therapy for the treatment of hyperlipidemia. Arch Intern Med. 1991 Sep; 151(9):1732-40.
    View in: PubMed
    Score: 0.098
  21. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
    View in: PubMed
    Score: 0.089
  22. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008 Mar; 197(1):12-24.
    View in: PubMed
    Score: 0.076
  23. Lipid responses in mildly hypertriglyceridemic men and women to consumption of docosahexaenoic acid-enriched eggs. Int J Vitam Nutr Res. 2003 Oct; 73(5):357-68.
    View in: PubMed
    Score: 0.057
  24. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014 Dec 16; 64(23):2525-40.
    View in: PubMed
    Score: 0.031
  25. Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids. Biochim Biophys Acta. 1992 Dec 10; 1180(2):147-62.
    View in: PubMed
    Score: 0.027
  26. Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia. Arterioscler Thromb. 1992 Oct; 12(10):1146-52.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.